scholarly journals Herpes zoster after inactivated COVID‐19 vaccine: a cutaneous adverse effect of the vaccine

2021 ◽  
Author(s):  
Pooja Arora ◽  
Kabir Sardana ◽  
Sinu Rose Mathachan ◽  
Purnima Malhotra
Keyword(s):  
Adverse Effect ◽  
Herpes Zoster ◽  
Cutaneous Adverse Effect

scholarly journals Bleomycin-induced flagellate pigmentation: a case report from North-East India

2019 ◽  
Vol 5 (4) ◽  
pp. 879
Author(s):  
Nandakishore Thokchom ◽  
Nandita Bhattacharjee ◽  
Linda Kongbam
Keyword(s):  
Adverse Effect ◽  
Case Report ◽  
Germ Cell ◽  
Targeted Therapies ◽  
Side Effect ◽  
Ovarian Teratoma ◽  
Germ Cell Tumours ◽  
North East India ◽  
North East ◽  
Cutaneous Adverse Effect

<p class="abstract">Bleomycin is an antitumour antibiotic commonly used in the management of Hodgkin’s lymphoma and germ cell tumours. Flagellate pigmentation is a very specific and rare cutaneous adverse effect of bleomycin. It is characterised by linear, painless, pruritic, hyperpigmented lesions simulating marks of whiplashes over trunk and extremities. With the advent of targeted therapies resulting in the infrequent use of bleomycin, this unique side effect is also uncommonly encountered nowadays. Here, we report a case of bleomycin-induced flagellate pigmentation in a 35-year-old Indian female with ovarian teratoma. The characteristic patterned hyperpigmented patches developed following 2nd cycle of chemotherapy with bleomycin, etoposide and cisplatin.</p><p class="abstract"> </p>

A rare and severe cutaneous adverse effect of telaprevir: drug rash with eosinophilia and systemic symptoms

2019 ◽  
Vol 154 (4) ◽  
Author(s):  
Fatma P. Cengiz ◽  
Ozlem Su ◽  
Nazan Emiroglu ◽  
Dilek Biyik Ozkaya ◽  
Anil G. Bahali ◽  
...  
Keyword(s):  
Adverse Effect ◽  
Cutaneous Adverse Effect ◽  
Drug Rash ◽  
Systemic Symptoms

Painful generalized erythematous patches: A very rare cutaneous adverse effect of pemetrexed

2015 ◽  
Vol 145 (8) ◽  
pp. 372-373
Author(s):  
María Castellanos-González ◽  
Javier Ballesteros Bargues
Keyword(s):  
Adverse Effect ◽  
Cutaneous Adverse Effect

scholarly journals Gemcitabine-induced skin necrosis

2018 ◽  
Vol 6 ◽  
pp. 2050313X1880926 ◽  
Author(s):  
Maria Monica Haydock ◽  
Saroj Sigdel ◽  
Toni Pacioles
Keyword(s):  
Adverse Effect ◽  
Skin Necrosis ◽  
Whipple Procedure ◽  
Chemotherapy Agent ◽  
Bullous Dermatosis ◽  
Cutaneous Adverse Effect ◽  
Cutaneous Reactions ◽  
Adenocarcinoma Of The Pancreas ◽  
Cutaneous Adverse Reactions ◽  
Gemcitabine Treatment

Since its emergence as a chemotherapy agent, gemcitabine has been associated with cutaneous adverse reactions. Rash is reported to be the most common cutaneous adverse effect. Other reported cutaneous reactions in the literature include bullous dermatosis, pseudocellulitis, subacute cutaneous lupus alopecia, and palmar–plantar erythrodysesthesia. Skin necrosis is a very rare adverse effect of this otherwise well-tolerated chemotherapeutic agent. In searching the literature, only one other case has been reported. In our report, we present a 74-year-old male with adenocarcinoma of the pancreas, status-post pancreaticoduodenectomy (Whipple procedure), who developed a rare case of skin necrosis of the lower leg 2 weeks after completing six cycles of monotherapy gemcitabine treatment.

Pyogenic Granuloma as a Cutaneous Adverse Effect of Vemurafenib

2014 ◽  
Vol 371 (13) ◽  
pp. 1265-1267 ◽  
Author(s):  
Stephen John Sammut ◽  
Nevianna Tomson ◽  
Pippa Corrie
Keyword(s):  
Adverse Effect ◽  
Pyogenic Granuloma ◽  
Cutaneous Adverse Effect

scholarly journals A rare cutaneous adverse effect secondary to cabozantinib therapy

2018 ◽  
Vol 2018 (12) ◽  
Author(s):  
Siona Growcott ◽  
Alexandra Banner ◽  
Adam Bray ◽  
Serena Hilman
Keyword(s):  
Adverse Effect ◽  
Cutaneous Adverse Effect

Famciclovir for Treatment of Herpesvirus Infections

1996 ◽  
Vol 30 (9) ◽  
pp. 978-985 ◽  
Author(s):  
Andrew D Luber ◽  
John F Flaherty
Keyword(s):  
Adverse Effect ◽  
Herpes Zoster ◽  
Antiviral Activity ◽  
Genital Herpes ◽  
Adverse Effect Profile ◽  
Suppressive Therapy ◽  
Absolute Bioavailability ◽  
Comparable Efficacy ◽  
Recurrent Genital Herpes ◽  
Oral Prodrug

OBJECTIVE: To discuss the antiviral activity, pharmacokinetics, clinical efficacy, and adverse effect profile of famciclovir, the oral prodrug of penciclovir (PCV), and to compare these features of famciclovir with those of acyclovir in the treatment of herpesvirus infections. DATA SOURCES: Literature was identified by MEDLINE search, and abstracts from recent meetings were included where relevant. Data provided by the manufacturer were also used. STUDY SELECTION: Data regarding antiviral activity were included if accepted and widely used methods were followed. Clinical trials in which a comparison with acyclovir or placebo was performed were given the highest priority. DATA SYNTHESIS: In comparison with acyclovir, PCV has similar antiviral activity although its mode of action is not identical. When administered orally, famciclovir, the oral prodrug of PCV, is better absorbed than acyclovir, yielding an absolute bioavailability of PCV of 77%. The predominant route of PCV elimination is via the kidneys, with a half-life of approximately 2.5 hours. In trials comparing famciclovir with acyclovir for the treatment of herpes zoster in immunocompetent individuals, comparable results were obtained. Famciclovir is also effective as therapy for recurrent episodes of genital herpes and may prove useful for chronic suppressive therapy. The most common adverse effects of famciclovir are headache and gastrointestinal upset. The dosage of famciclovir for herpes zoster in immunocompetent individuals is 500 mg po tid for 7 days; for recurrent genital herpes a dosage of 125 mg po bid for 5 days is recommended. Dosage adjustments are necessary in patients with renal dysfunction. CONCLUSIONS: Given its comparable efficacy, similar adverse effect profile, and less frequent dosing schedule than acyclovir, famciclovir represents a viable alternative for treatment of herpes zoster and for episodic therapy of recurrent genital herpes in immunocompetent adults. Specific recommendations for other uses of famciclovir await the publication of recent clinical trial results.

scholarly journals Disseminated granuloma annulare: A cutaneous adverse effect of anti-TNF agents

2011 ◽  
Vol 56 (6) ◽  
pp. 752 ◽  
Author(s):  
SibaP Raychaudhuri ◽  
Mondhipa Ratnarathorn ◽  
Stanley Naguwa
Keyword(s):  
Adverse Effect ◽  
Granuloma Annulare ◽  
Cutaneous Adverse Effect
Sign in / Sign up

Export Citation Format

Share Document